Diabetes Care publishes semaglutide trial in schizophrenia and prediabetes

The wire

1. 01The placebo-controlled HISTORI trial tested semaglutide 1.0 mg weekly for 30 weeks on insulin sensitivity and beta-cell function in patients with schizophrenia, prediabetes and obesity.
2. 02Antipsychotic-associated metabolic disease is a population clinicians struggle to treat, and randomized incretin data in this group has been scarce.
3. 03Full effect sizes, tolerability and psychiatric outcomes are in the published paper; the trial ran 30 weeks, so durability beyond that is untested.

From the source

Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX

Diabetes care · 2026 Sep 21 · Chen L, Wang J et al.